
September 2023 Community Letter from Ultragenyx
Ultragenyx Pharmaceuticals (sponsor of the GTX-102, an Antisense oligonucleotide for the potential treatment of Angelman syndrome) has issued a letter to both ASF and FAST providing an
Ultragenyx Pharmaceuticals (sponsor of the GTX-102, an Antisense oligonucleotide for the potential treatment of Angelman syndrome) has issued a letter to both ASF and FAST providing an
The Granville Angels of Ohio, the Renner and Rees family, are joining forces to support the Angelman syndrome community. On September 16th, they hosted their
We are entering a season full of changes! One of the first is that Elizabeth O’Connor is joining FAST as a development advisor, helping us
Here is a summary of a paper recently published out of the Journal of Autism and Developmental Disorders titled “Adaptive Skills of Individuals with Angelman